These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16732027)

  • 1. Frequent outpatient contact and decreasing medication affordability in patients with diabetes from 1997 to 2004.
    Grant RW; McCarthy EP; Singer DE; Meigs JB
    Diabetes Care; 2006 Jun; 29(6):1386-8. PubMed ID: 16732027
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
    Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
    Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in pharmaceutical treatment of diabetes and family financial burdens.
    Sarpong EM; Bernard DM; Miller GE
    Med Care Res Rev; 2012 Aug; 69(4):474-91. PubMed ID: 22513449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race/ethnicity and economic differences in cost-related medication underuse among insured adults with diabetes: the Translating Research Into Action for Diabetes Study.
    Tseng CW; Tierney EF; Gerzoff RB; Dudley RA; Waitzfelder B; Ackermann RT; Karter AJ; Piette J; Crosson JC; Ngo-Metzger Q; Chung R; Mangione CM
    Diabetes Care; 2008 Feb; 31(2):261-6. PubMed ID: 18000177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value-based insurance design for diabetes mellitus: approaches to optimal pharmacoeconomic implementation.
    Fendrick AM
    Am J Manag Care; 2010 Dec; 16(11 Suppl):S314-22. PubMed ID: 21517647
    [No Abstract]   [Full Text] [Related]  

  • 6. Variation in use of high-cost diabetes mellitus medications in the VA healthcare system.
    Gellad W; Mor M; Zhao X; Donohue J; Good C
    Arch Intern Med; 2012 Nov; 172(20):1608-9. PubMed ID: 23044980
    [No Abstract]   [Full Text] [Related]  

  • 7. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to diabetes care and medicines in the Philippines.
    Higuchi M
    Asia Pac J Public Health; 2010 Jul; 22(3 Suppl):96S-102S. PubMed ID: 20566540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevalence of diabetes mellitus in Germany 1998-2001. Secondary data analysis of a health insurance sample of the AOK in Hesse/KV in Hesse].
    Hauner H; Köster I; von Ferber L
    Dtsch Med Wochenschr; 2003 Dec; 128(50):2632-7. PubMed ID: 14673738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.
    Rathmann W; Haastert B; Icks A; Giani G
    Diabetes Care; 2007 Apr; 30(4):848-53. PubMed ID: 17392545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
    Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin Access and Affordability Working Group: Conclusions and Recommendations.
    Cefalu WT; Dawes DE; Gavlak G; Goldman D; Herman WH; Van Nuys K; Powers AC; Taylor SI; Yatvin AL;
    Diabetes Care; 2018 Jun; 41(6):1299-1311. PubMed ID: 29739814
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment and reply on: Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir.
    Freemantle N; Stella P; Munro V
    Curr Med Res Opin; 2007 Aug; 23(8):1761-2; author reply 1762-4. PubMed ID: 17588305
    [No Abstract]   [Full Text] [Related]  

  • 15. Access to diabetes care and treatment in Africa : challenges and opportunities.
    Beran D; Besançon S
    Med Sante Trop; 2018 Nov; 28(4):351-354. PubMed ID: 30799816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of demographic changes on drug utilization related to diabetes in Aquitaine].
    Taboulet F; Latry P; Fontaine S; Timmerman L
    Cah Sociol Demogr Med; 1999; 39(2-3):253-69. PubMed ID: 10615566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
    Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
    Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Insulin Boom. WHY THE COST OF THIS LIFESAVING DRUG IS REACHING NEW HEIGHTS.
    Tsai A
    Diabetes Forecast; 2016; 69(2):32-7. PubMed ID: 27048046
    [No Abstract]   [Full Text] [Related]  

  • 19. Value-based insurance plus disease management increased medication use and produced savings.
    Gibson TB; Mahoney J; Ranghell K; Cherney BJ; McElwee N
    Health Aff (Millwood); 2011 Jan; 30(1):100-8. PubMed ID: 21209445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy.
    Bruno G; Picariello R; Petrelli A; Panero F; Costa G; Cavallo-Perin P; Demaria M; Gnavi R
    Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):684-90. PubMed ID: 21907553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.